USA. Offering buprenorphine medication to people with opioid use disorder in jail may reduce rearrest and reconviction
USA. Offering buprenorphine medication to people with opioid use disorder in jail may reduce rearrest and reconviction
Massachusetts jails found that people with opioid use disorder who were incarcerated and received a medication approved to treat opioid use disorder, known as buprenorphine, were less likely to face rearrest and reconviction after release than those who did not receive the medication. After adjusting the data to account for baseline characteristics such as prior history with the criminal justice system, the study revealed a 32% reduction in rates of probation violations, reincarcerations, or court charges when the facility offered buprenorphine to people in jail compared to when it did not. The findings were published in Drug and Alcohol Dependence. (NIDA – National Institute on Drug Abuse, USA, 18.01.2022)
https://nida.nih.gov/news-events/news-releases/2022/01/offering-buprenorphine-medication-to-people-with-opioid-use-disorder-in-jail-may-reduce-rearrest-and-reconviction?utm